3871
Molecular correlates of response and survival in a phase II trial of weekly carboplatin/paclitaxel plus cemiplimab (wCP+C) in advanced/metastatic mucosal head and neck squamous cell carcinoma (a/mHNSCC).Mateus Trinconi Cunha, Fahad Rind, Priyanka Bhateja, Esmerina Tili, David Konieczkowski, Darrion Mitchell, Sujith Baliga, Sung Jun Ma, Simeng Zhu, Gogineni Emile, John Grecula, Nolan Seim, Catherine Harring, Lauren Miller, Abberly Lott Limbach, Kang Stephen, James W. Rocco, Christian Rolfo, Dukagjin Blakaj, Marcelo Bonomi
读摘要原文 →A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC)Hye Ryun Kim, Ye Guo, Cesar A. Perez, Robert Haddad, Ching-Yun Hsieh, Lei Liu, Nuttapong Ngamphaiboon, Song Qu, Saad Khan, Muh-Hwa Yang, Iris Xiang, Vivian Li, M. Brent McHenry, Jinhui Zhang, Ziwei Zhang, Kevin J. Harrington
读摘要原文 →IOB-032/PN-E40: A phase 2 study of neoadjuvant/adjuvant IO102-IO103 cancer vaccine plus pembrolizumab in resectable HNSCCBarbara Burtness, Ravindra Uppaluri, Michael J. Dennis, Annette M. Lim, Richard A. Scolyer, Erin Alesi, Ayako Wakatsuki Pedersen, Amy Wesa, Ravi K. Adapala, Ulla Kring Hansen, Marcos Iglesias, Bushi Wang, Cecilie Abildgaard, Qasim Ahmad, Francois Ringeisen, Georgina V. Long, Robert I. Haddad
读摘要原文 →